Antifibrinolytic Agent
Tranexamic Acid
The FDA lists this product in 32 strengths and forms.
Indications
Tranexamic Acid in Sodium Chloride Injection is indicated in patients with hemophilia for short-term use (two to eight days) to reduce the risk of hemorrhage during and following tooth extraction. Tranexamic Acid in Sodium Chloride Injection is an antifibrinolytic indicated in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction ( 1 ).
Contraindications
Tranexamic Acid in Sodium Chloride Injection is contraindicated:
- In patients with subarachnoid hemorrhage. Anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by tranexamic acid in such patients.
- In patients with active intravascular clotting [see Warnings and Precautions ( 5.1 )].
- In patients with history of hypersensitivity to tranexamic acid or any of the ingredients [see Warnings and Precautions ( 5.3 )] .
- In patients with subarachnoid hemorrhage, due to risk of cerebral edemaand cerebral infarction ( 4 ).
- In patients with active intravascular clotting ( 4 ).
- In patients with severe hypersensitivity reactions to tranexamic acid or any of the ingredients ( 4 ).
Warnings and precautions
- Risk of Thrombosis with concomitant use of Factor IX: Avoid concomitant use ( 5.1 ).
- Seizures: Inadvertent injection into neuraxial system may result in seizures ( 5.2 ).
- Hypersensitivity Reactions: In case of severe reaction, discontinue use seek immediate medical attention ( 5.3 ).
- Visual Disturbances: Visual or ocular adverse effects may occur. Discontinue use if visual or ocular symptoms occur ( 5.4 ).
- Dizziness may occur. Advise patients not to drive if dizziness occurs ( 5.5 ).